Mainland China’s regulatory evolution brings greater access to novel drugs
Clarivate
MAY 11, 2023
Hemophagocytic lymphohistiocytosis (HLH) Emapalumab Gamifant Swedish Orphan Biovitrum AB 2022 Patients with refractory or relapsed HLH HLH is an extremely rare, highly progressive hyperinflammatory disorder. No drugs are approved for the treatment of HLH and mortality rates are high (30-40%).
52 
Let's personalize your content